semaglutide glp 1 agonist other 2026-04-03 PubMed

Real-World Data Shows Semaglutide 2.4mg Lowers Heart Event Risk in ASCVD Patients

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.

Open on Pubmed ↗ Save (Pro)

Abstract

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study. Authors: Nanna MG, Mena-Hurtado C, Divino…

TitrateLab articles covering Semaglutide

Written by TitrateLab, separately from the study summarized above.

Peptide Lawsuits by Company: FDA Warnings, Penalties and Timelines · 2026-10-13
The Wegovy Pill Absorbs About 1 to 2%. Why Would a BPC-157 Capsule Do Better? · 2026-10-05
Medicare Part D Spending on Ozempic and Mounjaro in 2024 · 2026-09-08

semaglutide glp 1 agonist dose mentioned

Was this useful?